R&D Pipeline Therapy Areas
The agents and uses mentioned below are investigational and have not been approved by the US Food and Drug Administration (FDA) for the uses under investigation. No conclusions regarding safety and efficacy should be drawn for such agents and uses.
Sanofi is investigating multiple sources of damage in the brain that contribute to progression of multiple sclerosis (MS). Sanofi is also expanding the focus of its research to other neurological diseases, such as chronic inflammatory demyelinating polyneuropathy (CIDP).
Latest News from Sanofi
Educational Resources
General
Pre-approval Information Exchange: Overview of the Sanofi Specialty Care Pipeline
A presentation providing a brief general overview of Sanofi’s specialty care R&D pipeline, including investigational agents and proposed mechanistic targets in MS, and CIDP. All information is updated quarterly.
Multiple Sclerosis
Tolebrutinib Multiple Sclerosis Phase 2 Data
A discussion of the phase 2 clinical trial of tolebrutinib in the treatment of multiple sclerosis. This presentation includes details on patients characteristics, trial design, efficacy and safety data.
Phase 2b Dose-finding Study: NCT03889639; Link to Publication
Phase 2b Dose-finding Study: NCT03996291
Sanofi does not review or control the content of non-Sanofi websites.
Engage with Sanofi Specialty Care Payer Medical
Explore Other Therapy Areas
Immunology and Inflammation Resources
Oncology Resources
Rare Blood Disorders Resources
Member Engagement and Population Health Resources
